查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541673

2024-2032 年按疫苗類型（四價、三價）、技術（基於雞蛋、基於細胞）、年齡層（兒童、成人）、給藥途徑（注射、鼻噴霧）和地區分類的流感疫苗市場報告

Influenza Vaccine Market Report by Vaccine Type (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Age Group (Pediatric, Adult), Route of Administration (Injection, Nasal Spray), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球流感疫苗市場規模達67億美元。政府機構推出了許多促進疫苗接種計劃的有利舉措、流感和季節性爆發流行率的上升以及更有效和保護範圍更廣的流感疫苗的推出是推動全球市場的一些關鍵因素。

全球流感疫苗市場分析：

主要市場促進因素：流感疫苗市場的主要促進因素之一是醫療保健組織為提高公眾對流感疫苗接種重要性的認知而發起的越來越多的舉措。這些機構也組織健康教育活動，推動市場成長。此外，各國政府機構正在為老年人、醫護人員和兒童等優先年齡層提供補貼和免費疫苗接種，這反過來又改善了獲得疫苗的機會。

主要市場趨勢：流感疫苗市場的主要趨勢之一是主要參與者對四價疫苗生產和分銷的投資不斷增加。此外，重組和細胞方法等新技術的引入預計將在預測期內提振流感疫苗市場需求。

地理趨勢：根據報告，北美擁有最大的流感疫苗區域市場。醫療保健當局越來越注重優先考慮疫苗接種計劃和活動，這正在推動區域市場的發展。此外，北美完善的醫療基礎設施和對研發活動的廣泛投資也是重要的成長誘導因素。

競爭格局：流感疫苗市場的一些知名公司包括雅培實驗室、阿斯特捷利康公司、CSL Limited、第一三共有限公司、Emergent BioSolutions Inc.、F. Hoffmann-La Roche AG、Gamma Vaccines Pty Ltd、葛蘭素史克公司、默克公司& Co. Inc.、諾華公司、輝瑞公司、賽諾菲和 SINOVAC 等。

挑戰與機會：流感疫苗市場前景的主要挑戰之一是複雜的法規核准流程，這可能會對疫苗的分配產生負面影響。除此之外，擴大生產規模和確保各年齡層的功效和安全性的需求不斷成長，進一步阻礙了全球市場。然而，政府機構和公共衛生機構為確保流感疫苗易於獲得、有效並被個人接受而做出的持續努力將在未來幾年繼續促進流感疫苗市場的成長。

全球流感疫苗市場趨勢：

季節性流感爆發和流行病的增加

季節性流感病例的增加導致住院率上升。例如，根據 Statista Research 2023 年 12 月 6 日發布的報告，2022-2023 年流感季節美國有 3,100 萬流感病例。此外，2021-2022年流感季節期間，共有4,977人因流感死亡。除此之外，美國很大一部分人口未能接種疫苗。 2021-2022年，18-49歲族群中只有37%接種了流感疫苗，比例遠低於兒童和老年人。因此，醫療保健組織越來越重視流感疫苗接種的重要性，這正在促進市場成長。例如，2023年2月，世界衛生組織（WHO）公佈了2023-2024年流感季節流感疫苗病毒成分的建議。這項消息是在為期 4 天的流感病毒疫苗成分會議結束時的資訊發布會上宣布的。

對流感疫苗接種的意識不斷增強

季節性流感的日益普及主要推動了市場的成長。例如，2022年2月發布的全球流感資料提到，全球估計有10億人感染季節性流感。與此一致的是，報告也指出，在這10億人中，每年約有3至500萬人罹患嚴重流感。此外，根據世界衛生組織2022年12月公佈的資料，歐洲地區有5%-15%的人口受到流感影響。同樣，Plos One Journal 2021 年 7 月發表的文章提到，每年約有 5%-10% 和 20%-30% 的新流感感染病例發生在兒童和成人身上。流感病毒病例的增加正在提高人們對流感疫苗接種的認知，這為整體市場成長提供了積極的前景。除此之外，醫療保健組織正在發起活動，提供有關免疫接種益處的資訊，從而推動對流感疫苗的需求。例如，賽諾菲於2022 年6 月進行的一項醫療保健調查報告稱，藥劑師和醫生建議疾病管制與預防中心(CDC) 為65 歲及以上的人群提供Fluzone 高劑量四價疫苗等疫苗，用於治療流感。所有年齡層的個人日益成長的傾向將在預測期內繼續推動流感疫苗的市場佔有率。

政府機構日益成長的支持

全球各地的政府機構正在與主要公司合作，以支持與流感疫苗開發相關的研發活動。根據流感疫苗市場統計，2021年9月，美國疾病管制與預防中心（CDC）建立了由生物醫學高級研究與開發局（BARDA）協調的廣泛的機構間合作夥伴關係，支持新型流感疫苗的高級開發。此外，政府當局正在加強和放寬法規核准流程，這對流感疫苗市場的成長產生了積極影響。例如，2022年7月，美國FDA批准了葛蘭素史克生產四價疫苗Fluarix的請求。與此相適應，政府也投資與流感疫苗開發相關的臨床試驗和研發活動。例如，2022年3月，澳洲政府機構投資超過1億美元購買季節性流感疫苗，以保護處於危險中的個人。此外，主要醫療保健公司正在廣泛投資以疫苗形式引入先進療法。這反過來又支撐了流感疫苗市場的未來。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球流感疫苗市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疫苗類型

  • 四價
    • 市場趨勢
    • 市場預測
  • 三價
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依技術

  • 以雞蛋為主
    • 市場趨勢
    • 市場預測
  • 基於細胞的
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依年齡段

  • 兒科
    • 市場趨勢
    • 市場預測
  • 成人
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：依管理途徑

  • 注射
    • 市場趨勢
    • 市場預測
  • 鼻噴劑
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AstraZeneca plc
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gamma Vaccines Pty Ltd
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • SINOVAC
Product Code: SR112024A4206

The global influenza vaccine market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. The launch of numerous favorable initiatives by government bodies promoting vaccination programs, the rising prevalence of influenza and seasonal outbreaks, and the introduction of more effective and broadly protective influenza vaccines are some of the key factors driving the market globally.

Global Influenza Vaccine Market Analysis:

Major Market Drivers: One of the primary influenza vaccine market drivers is the growing initiatives launched by healthcare organizations to increase public awareness regarding the importance of influenza vaccinations. These agencies are also organizing health education campaigns, which are propelling the market growth. Furthermore, government bodies across countries are providing subsidies and free vaccinations for priority age groups, such as elderly individuals, healthcare workers, and children, which, in turn, is improving access to vaccines.

Key Market Trends: One of the primary influenza vaccine market trends is the rising investment by key players in the production and distribution of quadrivalent vaccines. In addition, the introduction of novel technologies, such as recombinant and cell-based approaches, is expected to bolster the influenza vaccine market demand over the forecasted period.

Geographical Trend: According to the report, North America holds the largest regional market for influenza vaccines. The increasing focus of healthcare authorities to prioritize vaccination programs and campaigns is driving the regional market. Furthermore, well-established healthcare infrastructures in North America and extensive investments in R&D activities are also acting as significant growth-inducing factors.

Competitive Landscape: Some of the prominent companies in the influenza vaccine market include Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and SINOVAC, among many others.

Challenges and Opportunities: One of the key challenges in the influenza vaccine market outlook is complex regulatory approval processes that can negatively impact the distribution of vaccines. In addition to this, the inflating need for scaling up production and ensuring efficacy and safety across various age groups is further hindering the global market. However, the rising efforts from government bodies and public healthcare organizations to ensure that influenza vaccines are accessible, effective, and accepted by individuals will continue to augment the influenza vaccine market growth in the coming years.

Global Influenza Vaccine Market Trends:

Increasing Seasonal Influenza Outbreaks and Pandemics

The rising cases of seasonal influenza are elevating the hospitalization rates. For example, according to the Statista Research report, published on December 6, 2023, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. In 2021-2022, only 37 % of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.

The Rising Awareness Towards Influenza Vaccination

The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high-dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.

The Growing Support from Government Bodies

Government bodies across the globe are collaborating with key companies to support R&D activities related to the development of influenza vaccines. As per the influenza vaccine market statistics, in September 2021, the Centers for Disease Control and Prevention (CDC) entered a broad inter-agency partnership coordinated by the Biomedical Advanced Research and Development Authority (BARDA) that supported the advanced development of novel influenza vaccines. Furthermore, government authorities are enhancing and easing the process of regulatory approvals, which is positively influencing the influenza vaccine market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. In line with this, the government is also investing in clinical trials and R&D activities related to the development of influenza vaccinations. For instance, in March 2022, the government bodies in Australia invested more than US$ 100 Million in the seasonal influenza vaccine to protect individuals at risk. Additionally, major healthcare companies are investing extensively in the introduction of advanced therapy in the form of vaccines. This, in turn, is bolstering the future of influenza vaccine market.

Influenza Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza vaccine market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

Quadrivalent

Trivalent

Quadrivalent represents the most popular type of influenza vaccine

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes quadrivalent and trivalent. According to the report, quadrivalent represented the largest segment.

Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.

Breakup by Technology:

Egg-based

Cell-based

Egg-based holds the largest share in the market

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes egg-based and cell-based. According to the report, egg-based accounted for the largest market share.

Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Breakup by Age Group:

Pediatric

Adult

Pediatric dominates the market

A detailed breakup and analysis of the market based on the age group has also been provided in the report. This includes pediatric and adult. According to the report, pediatric accounted for the largest market share.

Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.

Breakup by Route of Administration:

Injection

Nasal Spray

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes injection and nasal spray.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest regional market for influenza vaccines.

In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the influenza vaccine top companies are listed below:

Abbott Laboratories

AstraZeneca plc

CSL Limited

Daiichi Sankyo Company Limited

Emergent BioSolutions Inc.

F. Hoffmann-La Roche AG

Gamma Vaccines Pty Ltd

GlaxoSmithKline plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

SINOVAC

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Influenza Vaccine Market News:

March 2024: Osivax, a biopharmaceutical company, announced that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, which was a broad-spectrum influenza A vaccine and quadrivalent influenza vaccines (QIVs) candidate.

March 2024: Ahmedabad-based pharmaceutical company, Cadila Pharmaceuticals, announced the launch of a new influenza vaccine called Cadiflu Tetra.

February 2024: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of two vaccines for active immunization against the H5N1 subtype of the influenza A virus, which causes avian influenza or bird flu.

October 2023: Mylab in Pune and Serum Institute of India have launched Nasovac S4, India's first needle-free nasal influenza vaccine.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza vaccine market in 2023?
  • 2. What is the expected growth rate of the global influenza vaccine market during 2024-2032?
  • 3. What are the key factors driving the global influenza vaccine market?
  • 4. What are the key factors driving the global influenza vaccine market?
  • 5. What has been the impact of COVID-19 on the global influenza vaccine market?
  • 6. What is the breakup of the global influenza vaccine market based on the vaccine type?
  • 7. What is the breakup of the global influenza vaccine market based on the technology?
  • 8. What is the breakup of the global influenza vaccine market based on the age group?
  • 9. What are the key regions in the global influenza vaccine market?
  • 10. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Quadrivalent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Trivalent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Egg-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adult
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Injection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Nasal Spray
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CSL Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Daiichi Sankyo Company Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Gamma Vaccines Pty Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck & Co. Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Novartis AG
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 SINOVAC
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials

List of Figures

  • Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2023
  • Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2023
  • Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2023
  • Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
  • Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
  • Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million US$), 2024-2032
  • Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Influenza Vaccine Market: Competitive Structure
  • Table 8: Global: Influenza Vaccine Market: Key Players